Oneul E&M

At a glance

Oneul E&M filed 63 disclosures in the last 12 months, including 7 5% holder, 2 insider, 1 contract and 1 issuance. The most recent key filing was on Sep 11.

Revenue for 2025 was ₩16.7B, up 28.2% on 2024. It made an operating loss of ₩1.8B. Debt was 767% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.6B and operating loss of ₩1.8B.

The 2025 annual report lists 97 employees with an average tenure of 7 years and average pay of ₩39.8M, #1755 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩40.2M each on average. It paid no cash dividend for 2025. (주)오늘바이오 and related parties held 6.89% at year end.

From the 2025 annual report

Staff: 97 (68 men, 29 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.9B. Directors and auditors: 8, paid ₩321.7M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)오늘바이오 holds 3.60%; with 1 related party the group holds 6.89% of common shares at year end (from 20.38% at the start of the year).

Auditor: 삼덕 회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 44% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary